fig5
![Changes in hepatic fibrosis and incidence of HCC following direct-acting antiviral treatment of F3 chronic hepatitis c patients: a prospective observational study](https://image.oaes.cc/a64dc854-654e-4a24-a157-282bdd2262b0/5000.fig.5.jpg)
Figure 5. Cumulative hazard of HCC in patients with HCV after the end of DAA therapy, shown by Cox regression model according to gender. Cum: Cumulative; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; DAA: direct acting antiviral.
Figure 5. Cumulative hazard of HCC in patients with HCV after the end of DAA therapy, shown by Cox regression model according to gender. Cum: Cumulative; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; DAA: direct acting antiviral.
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/